NRC Health Capital Expenditures Incurred but Not yet Paid
NRC Health (NRC) reported Capital Expenditures Incurred but Not yet Paid of $378.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-04
- NRC Health capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$72.00K, a 115.13% decline year-over-year.
- NRC Health capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $450.00K, a 78.88% decline year-over-year.
- NRC Health capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $49.00K.
- NRC Health capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$2.31M, a 251.21% decline year-over-year.
- NRC Health capital expenditures incurred but not yet paid for fiscal 2025 was $347.00K, a 77.64% decline from fiscal 2024.
- NRC Health capital expenditures incurred but not yet paid for fiscal 2024 was $1.55M, a 24.88% decline from fiscal 2023.
- NRC Health capital expenditures incurred but not yet paid for fiscal 2023 was $2.07M, a 86.29% increase from fiscal 2022.
- NRC Health capital expenditures incurred but not yet paid for fiscal 2022 was $1.11M, a 13.28% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $378.00K 10-Q · filed 2026-08-04 | $427.00K derived: sum of 3 quarters · filed 2026-08-04 | -$1.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $450.00K 10-Q · filed 2026-05-06 | $499.00K derived: sum of 2 quarters · filed 2026-05-06 | -$1.81M derived: sum of 3 quarters · filed 2026-05-06 | -$1.33M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.26M derived: sum of 2 quarters · filed 2026-03-05 | -$1.78M derived: sum of 3 quarters · filed 2026-08-04 | $347.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.83M derived: sum of 2 quarters · filed 2026-08-04 | $298.00K 10-Q · filed 2025-11-07 | -$760.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $476.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.61M 10-Q · filed 2026-08-04 | $1.55M derived: sum of 3 quarters · filed 2026-08-04 | $3.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $2.13M 10-Q · filed 2026-05-06 | $1.07M derived: sum of 2 quarters · filed 2026-05-06 | $2.60M derived: sum of 3 quarters · filed 2026-05-06 | $1.02M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $469.00K derived: sum of 2 quarters · filed 2026-03-05 | -$1.11M derived: sum of 3 quarters · filed 2026-03-05 | $1.55M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$54.00K derived: sum of 2 quarters · filed 2025-11-07 | $2.61M 10-Q · filed 2025-11-07 | $2.86M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | -$1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $1.08M 10-Q · filed 2025-08-08 | $1.33M derived: sum of 3 quarters · filed 2026-03-05 | $1.37M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $2.66M 10-Q · filed 2025-05-09 | $2.91M derived: sum of 2 quarters · filed 2026-03-05 | $2.95M derived: sum of 3 quarters · filed 2026-03-05 | $3.22M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $289.00K derived: sum of 2 quarters · filed 2026-03-05 | $559.00K derived: sum of 3 quarters · filed 2026-03-05 | $2.07M 10-K · filed 2026-03-05 |
| 2023-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $312.00K derived: sum of 2 quarters · filed 2024-11-08 | $1.82M 10-Q · filed 2024-11-08 | $2.69M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $270.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.78M 10-Q · filed 2024-08-08 | $2.64M derived: sum of 3 quarters · filed 2025-03-17 | $2.08M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $1.51M 10-Q · filed 2024-05-09 | $2.37M derived: sum of 2 quarters · filed 2025-03-17 | $1.81M derived: sum of 3 quarters · filed 2025-03-17 | $2.45M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $867.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $302.00K derived: sum of 2 quarters · filed 2025-03-17 | $941.00K derived: sum of 3 quarters · filed 2025-03-17 | $1.11M 10-K · filed 2025-03-17 |
| 2022-09-30 | -$565.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $74.00K derived: sum of 2 quarters · filed 2023-11-09 | $242.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $639.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $807.00K 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $168.00K 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | $979.00K 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $127.00K 10-K · filed 2023-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |